News

Press Releases

Biocure teams up with Y Biologics in cancer

DATE : 2019.01.14

 

Biocure Technology (OTCQB:BICTF) subsidiary BiocurePharm, Korea inks a collaboration agreement with South Korea-based Y Biologics aimed at researching the effectiveness of its anti-CD19 CAR-T candidate combined with Y's PD-1 inhibitor in solid tumors.

Financial terms are not disclosed.